300 The American Road
United States - Map
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases. The company is developing Yttrium-90-labeled clivatuzumab tetraxetan, which is in Phase III registration study used for the treatment of pancreatic cancer. It is also developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAM5-SN-38 ADC that is in Phase II trials for the treatment of metastatic colorectal cancer; and epratuzumab, which is in two Phase III clinical trials for the treatment of systemic lupus erythematosus. Its early-stage products include Veltuzumab, a humanized monoclonal antibody targeting CD20 receptors on B lymphocytes for the treatment of non-Hodgkin lymphoma (NHL) and autoimmune diseases; Milatuzumab, a humanized monoclonal antibody targeting tumors that expresses the CD74 antigen, which is in Phase 1 studies; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled anti-CD22 investigational product candidate for patients with NHL or acute lymphoblastic leukemia; and IMMU-114, a novel humanized antibody for the treatment of patients with B-cell cancers. The company also provides LeukoScan, a diagnostic imaging product for diagnostic imaging to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
|Immunomedics Inc.’s ISS Governance QuickScore as of Nov 1, 2015 is 3. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 1; Compensation: 7.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. David M. Goldenberg ,
Founder, Chairman of The Board, Chief Scientific Officer and Chief Patent Officer
|Ms. Cynthia L. Sullivan ,
Chief Exec. Officer, Pres, Director and Pres of Ibc Pharmaceuticals Inc
|Mr. Peter P. Pfreundschuh ,
Chief Financial Officer and VP of Fin.
|Ms. Phyllis Parker ,
Director of Admin.
|Dr. Chau Cheng ,
Sr. Director of Investor Relations & Grant Management and Corp. Sec.
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|